TRPV1 and TRPA1 Agonist Composition for Adrenomedullin Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compositions fail to effectively enhance adrenomedullin gene expression, which is crucial for physiological activities such as vasodilation, angiogenesis, antimicrobial action, anti-bowel inflammation, and thrombogenesis prevention.
Innovation Solution
A composition comprising a TRPV1 agonist and a TRPA1 agonist, specifically capsaicin, 6-shogaol, piperine, allyl isothiocyanate, cinnamaldehyde, diallyl disulfide, and oxylipin, synergistically enhances adrenomedullin gene expression in epithelial cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a single agonist (TRPV1 or TRPA1) is used to enhance adrenomedullin gene expression, then some enhancement effect is achieved, but the effect is insufficient compared to combination therapy
Solution Approach 1:
The patent combines TRPV1 agonist and TRPA1 agonist into a single composition to achieve synergistic enhancement of adrenomedullin gene expression. The combination of capsaicin (TRPV1 agonist) and allyl isothiocyanate (TRPA1 agonist) produces a greater effect than either agonist alone, directly resolving the contradiction between achieving reliable enhancement and maximizing expression levels.
Solution Approach 2:
The invention creates a composite pharmaceutical composition containing both TRPV1 and TRPA1 agonists. This composite approach allows the two different agonists to work together synergistically, achieving higher adrenomedullin gene expression levels than single-agonist treatments, thus resolving the contradiction between reliability and productivity.
2Reliability
If herbal medicine Daiken chuto containing multiple components is used, then adrenomedullin release is promoted, but the mechanism is complex and involves multiple TRP channels
Solution Approach 1:
The patent extracts and isolates the key active components from the complex herbal medicine Daiken chuto. By identifying and using specific TRPV1 agonists (like capsaicin) and TRPA1 agonists (like allyl isothiocyanate), the invention simplifies the complex multi-component herbal formulation into a defined combination of two primary agonists, reducing complexity while maintaining effectiveness.
Solution Approach 2:
The invention segments the complex herbal medicine into two distinct functional components: TRPV1 agonist and TRPA1 agonist. This segmentation allows for a better understanding of the mechanism of action and creates a more manageable composition with defined roles for each component, addressing the complexity issue while preserving the adrenomedullin release promotion effect.
3Adaptability or versatility
If TRP channel agonists are used for multiple physiological activities, then versatility is improved, but specificity of action may be reduced
Solution Approach 1:
The patent applies local quality by targeting specific TRP channels (TRPV1 and TRPA1) with their respective agonists to achieve adrenomedullin gene expression enhancement. While TRP channels have broad physiological roles, the combination therapy specifically targets adrenomedullin production in intestinal epithelial cells, providing specificity in the desired outcome while maintaining versatility in the underlying mechanism.
Data Source
AI summary
The present invention provides a composition having an action to enhance adrenomedullin gene expression. One or more embodiments of the present invention relate to a composition for enhancing adrenomedullin gene expression containing a TRPV1 agonist and a TRPA1 agonist as active ingredients. The TRPV1 agonist can be, for example, at least one selected from capsaicin, 6-shogaol, 6-gingerol and piperine. The TRPA1 agonist can be, for example, at least one selected from allyl isothiocyanate, cinnamaldehyde, diallyl disulfide, ASP7663 and oxylipin.